Where does Pharmaxis Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Pharmaxis Ltd. ranks #42,322 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Pharmaxis Ltd. hold?

Pharmaxis Ltd. holds 6 US utility patents granted between 2017 and 2021, spanning 4 technology areas.

What is Pharmaxis Ltd.'s Innovation Score?

Pharmaxis Ltd. has an Innovation Score of 28.7 out of 100 (28th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Pharmaxis Ltd.'s patent grant rate increasing or decreasing?

Pharmaxis Ltd.'s recent grant velocity is +100% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Pharmaxis Ltd.'s patents?

Pharmaxis Ltd.'s patents average 24.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Pharmaxis Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Pharmaxis Ltd.

Q: What technology areas does Pharmaxis Ltd. focus on?

Pharmaxis Ltd.'s top technology area is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor) with 3 patents, ranking #1,777 of 3,490 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

USPTO PatentsView assignee record - 6 granted patents across 4 technology areas, recorded in grant years 2017–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Pharmaxis ranks #42,322 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 4 technology areas.

#42,322
of 49,997 US assignees by volume: 28th percentile
by Innovation Score (28.7/100): 24.8
avg claims per patent: +100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R42322 · Foreign Corporation #42,322 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 6 grants
LOWER-Q #42,322/49,997
PHOTO-FINISH Phacil
CPC-NARROW A61M · 4 areas
INNOV-THIN 28.7/100
CLAIMS-DENSE 24.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Phacil, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Pharmaxis’s 28.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (23%) Velocity 0.0 pts (0%) Breadth 7.1 pts (25%) Claim depth 14.9 pts (52%)

Qualcomm Incorporated · highest

85
Pharmaxis · this assignee

29
3D Lighting… · lowest

7

What this shows Pharmaxis's Innovation Score is 28.7/100 (28th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Pharmaxis?

Each dot is one of Pharmaxis’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Pharmaxis’s own 24.8 claims/patent is ABOVE the 15.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Pharmaxis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Pharmaxis's grants concentrate

Pharmaxis Ltd. is a focused PatentsView assignee: 4 CPC subclasses with 50% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2020 (3 grants) versus a trough of 1 in 2017. By volume, Pharmaxis sits between Phacil, LLC and Phoenix Tailings, Inc..

Phacil

6
Phantom Cyber

6
Pharmafluidics

6
Pharmaq AS

6
Phase 2

6
Philips Healthcar…

6
Phineas Products

6
Phoenix Tailings

6
Pharmaxis ◀

6

What this shows Pharmaxis holds 6 patents at rank #42,382, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Pharmaxis

By rank, the assignees closest to #42,382 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Pharmaxis's primary technology class.

Pharmaxis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 28th percentile higher than 28% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Pharmaxis Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	16.7%
2019	1	16.7%
2020	3	50.0%
2021	1	16.7%

Which technologies does Pharmaxis Ltd. patent most?

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 3

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

C07D - Heterocyclic Compounds 3

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Pharmaxis Ltd.'s patent record in context - here's where to go next.

Pharmaxis Ltd.'s lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 50% of its portfolio - see every assignee active in that class. Explore A61M
Ranked #42,322 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Pharmaxis Ltd. against Phacil, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 28.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.